ME02648B - Jedinjenje pirazin karboksamida - Google Patents

Jedinjenje pirazin karboksamida

Info

Publication number
ME02648B
ME02648B MEP-2017-43A MEP201743A ME02648B ME 02648 B ME02648 B ME 02648B ME P201743 A MEP201743 A ME P201743A ME 02648 B ME02648 B ME 02648B
Authority
ME
Montenegro
Prior art keywords
amino
carboxamide
phenyl
salt
methylpiperazin
Prior art date
Application number
MEP-2017-43A
Other languages
German (de)
English (en)
French (fr)
Inventor
Takahiro Matsuya
Yutaka Kondoh
Itsuro Shimada
Shigetoshi Kikuchi
Kenichi Onda
Hiroki Fukudome
Yukihiro Takemoto
Nobuaki Shindou
Hideki Sakagami
Hisao Hamaguchi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02648(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of ME02648B publication Critical patent/ME02648B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (13)

1.Jedinjenje formule (I) ili so istog: (gde R1 predstavlja piperazinil koji je supstituisan sa C1-6 alkilom, piperidinil koji je supstituisan sa C1-6 alkilom, ili piperidinil supstituisan sa piperazinilom koji može biti supstituisan sa C1-6 alkilom, Prsten A predstavlja benzen koji može biti supstituisan sa jednim ili više supstituenata odabranih iz grupe koja se sastoji od halogena, C1-6 alkila koji može biti supstituisan sa jednim ili više atoma halogena, i -O-C1-6 alkila, pirazola koji može biti supstituisan sa C1-6 alkilom, imidazola koji može biti supstituisan sa C1-6 alkilom ili pirimidinom koji može biti supstituisan sa C1-6 alkilom, L1 predstavlja NH-, R2 predstavlja H ili C1-6 alkil, L2 predstavlja -O- ili vezu, Y predstavlja Prsten X, Prsten X predstavlja aromatični heterocikl, nearomatični heterocikl, cikloalkan, ili benzen koji može biti supstituisan sa jednim ili više supstituenata izabranih iz grupe koja se sastoji od halogena, -O- C1-6 alkila, -CN, cikloalkila, arila, aromatične heterociklične grupe, ne-aromatične heterociklične grupe koja može biti supstituisana sa C1-6 alkil, okso, i C1-6 alkilom koji može biti supstituisan sa jednim ili više atoma halogena, L3 predstavlja -NH-, -N(C1-6 alkil)- ili vezu, M predstavlja -C(O), R3 predstavlja H, R4 predstavlja H.)
2. Jedinjenje ili so istog prema patentnom zahtevu 1, gde je L2 -O-, Prsten X je benzen koji može biti supstituisan sa C1-6 alkilom, i L3 je -NH-.
3. Jedinjenje ili so istog prema patentnom zahtevu 1, gde je L2 -O-, Prsten X je nearomatični heterocikl, i L3 je veza.
4. Jedinjenje ili so istog prema patentnom zahtevu 1, gde je L2 veza, Prsten X je nearomatični heterocikl, a L3 je veza.
5. Jedinjenje ili so istog prema patentnom zahtevu 3, gde je Prsten X pirolidin ili piperidin.
6. Jedinjenje ili so istog prema patentnom zahtevu 4, gde je Prsten X piperidin ili tetrahidropiridin.
7. Jedinjenje ili so istog prema patentnom zahtevu 1, koje je 5-[3-(akriloilamino)fenoksi]-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)-2-metilfenoksi]-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil]amino} pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-izopropil-3-{[4-(4-metilpiperazin-1-il)fenil]amino} pirazin-2-karboksamid, 5-(1-akriloilpiperidin-4-il)-6-etil-3-({3-metil-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-3-{[4-(4-metilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-etil-3-{[4-metoksi-3-(4-metilpiperazin-1-il)fenil] amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-etil-3-{[4-(4-etilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid, 5-{[(3R)-1-akriloilpirolidin-3-il]oksi}-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-6-izopropil-3-{[1-(1-metilpiperidin-4-il)-1H-pirazol-4-il]amino}pirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-3-({4-[(3S)-3,4-dimetilpiperazin-1-il]fenil}amino)-6-etilpirazin-2-karboksamid, 5-[3-(akriloilamino)fenoksi]-3-({4-[(3R)-3,4-dimetilpiperazin-1-il]fenil}amino)-6-etilpirazin-2-karboksamid, 5-(1-akriloilpiperidin-4-il)-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil} amino)pirazin-2-karboksamid, 5-{[(3R)-1-akriloilpirolidin-3-il]oksi}-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil] amino}pirazine-2-karboksamid, 5-{[(3R)-1-akriloilpiperidin-3-il]oksi}-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, 5-{[(3R)-1-akriloilpiperidin-3-il]oksi}-6-etil-3-({3-metil-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid, ili 5-[5-(akriloilamino)-2-fluorofenoksi]-6-etil-3-{[4-(4-metilpiperazin-1-il)fenil]amino} pirazin-2-karboksamid, ili so istog.
8. Farmaceutska kompozicija koja sadrži jedinjenje ili so istog prema patentnom zahtevu 7, i farmaceutski prihvatljiv ekscipijens.
9. Primena jedinjenja ili soli istog prema patentnom zahtevu 7, za proizvodnju farmaceutske kompozicije za prevenciju i/ili lečenje kancera pozitivnog na EGFR T790M mutaciju.
10. Jedinjenje ili so istog prema patentnom zahtevu 7 za primenu u lečenju kancera pozitivnog na EGFR T790M mutaciju.
11. Jedinjenje ili so istog prema patentnom zahtevu 7, koje je 5-[3-(akriloilamino)fenoksi]-6-izopropil-3-{[4-(4-metilpiperazin-1-il)fenil]amino}pirazin-2-karboksamid ili so istog.
12. Jedinjenje ili so istog prema patentnom zahtevu 7, koje je 5-(1-akriloilpiperidin-4-il)-6-etil-3-({3-metil-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil}amino)pirazin-2-karboksamid ili so istog.
13. Jedinjenje ili so istog prema patentnom zahtevu 7, koje je 5-{[(3R)-1-akriloilpirolidin-3-il]oksi}-6-etil-3-({4-[4-(4-metilpiperazin-1-il)piperidin-1-il]fenil} amino)pirazin-2-karboksamid ili so istog.
MEP-2017-43A 2012-01-17 2013-01-15 Jedinjenje pirazin karboksamida ME02648B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012007525 2012-01-17
PCT/JP2013/050579 WO2013108754A1 (ja) 2012-01-17 2013-01-15 ピラジンカルボキサミド化合物
EP13738947.4A EP2805940B1 (en) 2012-01-17 2013-01-15 Pyrazine carboxamide compound

Publications (1)

Publication Number Publication Date
ME02648B true ME02648B (me) 2017-06-20

Family

ID=48799179

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-43A ME02648B (me) 2012-01-17 2013-01-15 Jedinjenje pirazin karboksamida

Country Status (29)

Country Link
US (1) US9085540B2 (me)
EP (1) EP2805940B1 (me)
JP (1) JP5532366B2 (me)
KR (1) KR101985050B1 (me)
CN (1) CN104080774B (me)
AR (1) AR089727A1 (me)
AU (1) AU2013210438B2 (me)
BR (1) BR112014017466A8 (me)
CA (1) CA2860765C (me)
CY (1) CY1118644T1 (me)
DK (1) DK2805940T3 (me)
EA (1) EA026353B1 (me)
ES (1) ES2613399T3 (me)
HR (1) HRP20170226T1 (me)
HU (1) HUE033177T2 (me)
IL (1) IL233437A (me)
LT (1) LT2805940T (me)
ME (1) ME02648B (me)
MX (1) MX355434B (me)
PH (1) PH12014501456A1 (me)
PL (1) PL2805940T3 (me)
PT (1) PT2805940T (me)
RS (1) RS55704B1 (me)
SI (1) SI2805940T1 (me)
SM (2) SMT201700094T1 (me)
TW (1) TWI532727B (me)
UA (1) UA111010C2 (me)
WO (1) WO2013108754A1 (me)
ZA (1) ZA201405045B (me)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014163161A1 (ja) * 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
US10329270B2 (en) * 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2015182628A1 (ja) * 2014-05-28 2015-12-03 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
KR20170105021A (ko) * 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
RU2017140923A (ru) 2015-04-27 2019-05-27 Астеллас Фарма Инк. Стабилизированная фармацевтическая композиция
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
BR112017025986A2 (pt) * 2015-06-02 2018-08-14 Pharmacyclics Llc inibidores de tirosina quinase de bruton.
ES2824576T3 (es) * 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
TWI804987B (zh) 2015-12-24 2023-06-11 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
JPWO2018079570A1 (ja) 2016-10-26 2019-09-19 アステラス製薬株式会社 安定な医薬組成物
CN108419436B (zh) * 2016-12-09 2021-05-04 深圳市塔吉瑞生物医药有限公司 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
SG11201912770SA (en) * 2017-06-23 2020-01-30 Kyowa Kirin Co Ltd a, ß-UNSATURATED AMIDE COMPOUND
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
JP7201800B2 (ja) * 2018-09-30 2023-01-10 メッドシャイン ディスカバリー インコーポレイテッド Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
CN112062728A (zh) * 2019-05-25 2020-12-11 上海鑫凯化学科技有限公司 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法
EP4058435A1 (en) * 2019-11-13 2022-09-21 Genentech, Inc. Therapeutic compounds and methods of use
CN111266090B (zh) * 2020-02-19 2022-11-15 渤海大学 一种快速吸附和选择性分离阳离子染料污染物的吸附分离材料及其应用
WO2021244505A1 (zh) * 2020-06-01 2021-12-09 微境生物医药科技(上海)有限公司 新型吡嗪化合物
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN117624131A (zh) * 2020-09-30 2024-03-01 百济神州有限公司 作为hpk1抑制剂的3-[(1h-吡唑-4-基)氧基]吡嗪-2-胺化合物和其用途
EP4308559A1 (en) 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1670473A1 (en) 2003-09-15 2006-06-21 Wyeth a Corporation of the State of Delaware Substituted quinolines as protein tyrosine kinase enzyme inhibitors
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP5600063B2 (ja) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
KR20100132550A (ko) * 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
CA2723205C (en) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
MX2011011875A (es) * 2009-05-08 2011-12-08 Astellas Pharma Inc Compuesto de carboxamida heterociclica diamino.
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Also Published As

Publication number Publication date
EP2805940B1 (en) 2016-11-23
HK1203491A1 (en) 2015-10-30
PH12014501456A1 (en) 2014-10-08
US20140323463A1 (en) 2014-10-30
AU2013210438B2 (en) 2016-11-10
SI2805940T1 (sl) 2017-04-26
CN104080774A (zh) 2014-10-01
MX355434B (es) 2018-04-18
BR112014017466A2 (pt) 2017-06-13
RS55704B1 (sr) 2017-07-31
CA2860765C (en) 2018-06-26
IL233437A (en) 2017-01-31
EA201491371A1 (ru) 2014-11-28
WO2013108754A1 (ja) 2013-07-25
HUE033177T2 (en) 2017-11-28
JPWO2013108754A1 (ja) 2015-05-11
CA2860765A1 (en) 2013-07-25
PT2805940T (pt) 2017-02-03
SMT201700094B (it) 2017-03-08
KR101985050B1 (ko) 2019-05-31
UA111010C2 (uk) 2016-03-10
CN104080774B (zh) 2017-02-22
PL2805940T3 (pl) 2017-06-30
ZA201405045B (en) 2016-01-27
JP5532366B2 (ja) 2014-06-25
SMT201700094T1 (it) 2017-03-08
CY1118644T1 (el) 2017-07-12
IL233437A0 (en) 2014-08-31
ES2613399T3 (es) 2017-05-24
AU2013210438A1 (en) 2014-07-17
AR089727A1 (es) 2014-09-10
BR112014017466A8 (pt) 2017-07-04
TW201341373A (zh) 2013-10-16
LT2805940T (lt) 2017-01-10
HRP20170226T1 (hr) 2017-04-07
TWI532727B (zh) 2016-05-11
EP2805940A4 (en) 2015-04-15
DK2805940T3 (en) 2017-02-06
EP2805940A1 (en) 2014-11-26
US9085540B2 (en) 2015-07-21
EA026353B1 (ru) 2017-03-31
MX2014008647A (es) 2014-11-25
KR20140114404A (ko) 2014-09-26

Similar Documents

Publication Publication Date Title
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
HRP20100522T1 (hr) Piridin karboksamidi kao inhibitori 11-beta-hsd1
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
RU2019132254A (ru) Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
HRP20151435T1 (hr) Diamino heterociklički karboksamidni spoj
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
PE20140502A1 (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
CA2585053A1 (en) Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
AR092045A1 (es) Combinaciones farmaceuticas
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
JP2010508338A5 (me)
ME02200B (me) Postupci za korisćenje alk inhibitora
HRP20220414T1 (hr) Inhibitori lizin specifične demetilaze-1
NZ620635A (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
RU2011146363A (ru) Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета
HRP20141199T1 (hr) Kombinacija od spoja glyt1 s antipsihoticima
HRP20140252T1 (hr) Derivati imidazola kao inhibitori kazeinske kinaze
NZ630488A (en) Piperidine derivatives for gpr119 agonist
JP2013536194A5 (me)
HRP20221454T1 (hr) Piridinamin-piridonski i pirimidinamin-piridonski spojevi
PE20051170A1 (es) DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa